PCAS Valuation

Is PCA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PCA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PCA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PCA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PCA?

Key metric: As PCA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PCA. This is calculated by dividing PCA's market cap by their current earnings.
What is PCA's PE Ratio?
PE Ratio	12.5x
Earnings	€8.76m
Market Cap	€109.93m

PCA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	-16.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does PCA's PE Ratio compare to its peers?

The above table shows the PE ratio for PCA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	39.5x
ALECR Eurofins-Cerep	13.1x	n/a	€99.9m
ERF Eurofins Scientific	27.5x	18.3%	€9.0b
DIM Sartorius Stedim Biotech	108.1x	31.9%	€17.4b
GNFT Genfit	9.2x	41.2%	€204.4m
PCA PCAS	12.5x	n/a	€109.9m

Price-To-Earnings vs Peers: PCA is good value based on its Price-To-Earnings Ratio (12.5x) compared to the peer average (24.5x).

Price to Earnings Ratio vs Industry

How does PCA's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: PCA is good value based on its Price-To-Earnings Ratio (12.5x) compared to the European Life Sciences industry average (39.9x).

Price to Earnings Ratio vs Fair Ratio

What is PCA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PCA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	12.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PCA's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sanofi

€116.3b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€92.79

1.4%

7.1%

Vetoquinol

€934.8m

A veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.

VETO

€79.00

-3.8%

-13.2%

Eurofins Scientific

€9.0b

Provides various analytical testing and laboratory services worldwide.

ERF

€47.41

4.0%

-10.6%